Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety

被引：0
|
作者：
Paola Ponzani
Cesare Berra
Alessandra Di Lelio
Paola Del Sindaco
Chiara Di Loreto
Francesco Reggiani
Giuseppe Lucisano
Maria Chiara Rossi
机构：
[1] ASL3 Genovese,SSD Endocrinologia, Diabetologia e Malattie Metaboliche
[2] Humanitas Research Institute,Servizio di Diabetologia del Perugino
[3] Center for Outcomes Research and Clinical Epidemiology (CORESEARCH),undefined
[4] USL Umbria 1,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Effectiveness; Glycemic variability; Hypoglycemia; Insulin degludec; Real-world data; Type 1 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [1] Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
    Ponzani, Paola
    Berra, Cesare
    Di Lelio, Alessandra
    Del Sindaco, Paola
    Di Loreto, Chiara
    Reggiani, Francesco
    Lucisano, Giuseppe
    Rossi, Maria Chiara
    [J]. DIABETES THERAPY, 2020, 11 (01) : 97 - 105
  • [2] Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data
    Landstedt-Hallin, Lena
    Gundgaard, Jens
    Ericsson, Asa
    Ellfors-Zetterlund, Susanne
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 647 - 655
  • [3] Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data
    Gundgaard, J.
    Landstedt-Hallin, L.
    Ericsson, A.
    Ellfors-Zetterlund, S.
    [J]. DIABETOLOGIA, 2016, 59 : S7 - S7
  • [4] Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study
    Harris, Stewart B.
    Ajala, Olubukola
    Bari, Basel
    Liutkus, Joanne
    Hahn, Jina
    Martyn, Oliver
    Zwicker, Deborah
    [J]. DIABETES THERAPY, 2021, 12 (06) : 1689 - 1702
  • [5] Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study
    Stewart B. Harris
    Olubukola Ajala
    Basel Bari
    Joanne Liutkus
    Jina Hahn
    Oliver Martyn
    Deborah Zwicker
    [J]. Diabetes Therapy, 2021, 12 : 1689 - 1702
  • [6] ANNUAL COST AND EFFECTS OF SWITCHING TO INSULIN DEGLUDEC FROM OTHER BASAL INSULINS: EVIDENCE FROM SWEDISH REAL-WORLD DATA
    Gundgaard, J.
    Landstedt-Hallin, L.
    Ericsson, A.
    Ellfors-Zetterlund, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A673 - A673
  • [7] Clinical Utility of Switching to Insulin Degludec from Other Basal Insulins in Patients with Type 1 or 2 Diabetes
    Baran, O.
    Dersch-Mills, D.
    Bakal, J.
    Arbo, T.
    Hnatiuk, M.
    Roedler, R.
    [J]. CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2021, 74 (02): : 185 - 185
  • [8] Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Katamine, Aki
    Kondo, Yuichiro
    Babazono, Tetsuya
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (11) : 1983 - 1991
  • [9] Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
    Paola Ponzani
    Cesare Berra
    Alessandra Di Lelio
    Paola Del Sindaco
    Chiara Di Loreto
    Francesco Reggiani
    Giuseppe Lucisano
    Maria Chiara Rossi
    [J]. Diabetes Therapy, 2018, 9 : 2209 - 2218
  • [10] Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
    Ponzani, Paola
    Berra, Cesare
    Di Lelio, Alessandra
    Del Sindaco, Paola
    Di Loreto, Chiara
    Reggiani, Francesco
    Lucisano, Giuseppe
    Rossi, Maria Chiara
    [J]. DIABETES THERAPY, 2018, 9 (06) : 2209 - 2218
12345